Federal contract award
HHSO100201600039C
IGF::OT::IGF INACTIVATED ZIKA VIRUS VACCINE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 325414 — Biological Product (except Diagnostic) Manufacturing |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $18.8M |
| Current contract value | $18.8M |
| Potential contract value / ceiling | $149.2M |
| Start date | Oct 1, 2016 |
| Current end date | Jul 15, 2022 |
| Potential end date | Jul 15, 2022 |
| Latest award activity | Apr 8, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 8, 2026 | P00008 | $-14.6M | NO-COST SUPPLEMENTAL AGREEMENT TO INCORPORATE BY EXECUTIVE ORDER 14042 - FAR DEVIATION CLAUSE 52.223-99, ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS. NO OTHER CHANGES APPLY. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.